Organ-specific organoid culture material not only provides the optimal environment for organoid growth, but also shows high tissue repair capacity when grafted. We achieved standardization and optimization of organoid culture methods of more than 10 organoids using the organ-specific culture material developed in-house.

Organoid disease models representing incurable diseases like AD, NASH, IPF can be used to investigate the pathogenesis of each disease and to discover the therapeutic agents. The models can also reflect both genetic and environmental factors of the corresponding disease.

When using Cellartgen’s organoid drug evaluation platform, we can screen numerous new drug candidates rapidly. To add on, by replacing the preclinical safety test, it can minimize the cost and the time used up in the clinical testing.

As advanced biomaterial is a fundamental skill for the commercialization of organoid regenerative therapy, we are securing advanced biomaterial technology.

Cellartgen’s functional hydrogel has high biocompatibility and outstanding adhesion strength which maximizes the drug delivery efficiency. In addition to the drug and cell therapy delivery support, it can also be applied to organoid technology, for instance, as the main material for producing organoid cluster “Assembloid”.

Lipid Nanoparticles (LNP), unlike viral vectors, have the advantage of safety due to low immunogenicity and oncogenicity. Cellartgen’s LNP can not only be applied for gene therapy and vaccine development, but also for tissue reprogramming that can turn specific tissue into a desired tissue.